BioClinica will look to leverage Medici’s specialized services, including its ability to recruit and retain orphan disease and unique patient populations for hard-to-recruit trials.
Medici’s 40 employees will relocate to BioClinica’s Audobon facility in January, BioClinica CEO John Hubbard told Outsourcing-Pharma.com.
Hubbard added: “Medici will bring an array of digital and specialized patient recruitment and retention services to BioClinica’s global clinical trial network (CCBR) and other service and technology offerings such as patient insights, patient locate services and more. Additionally, analytics are fundamental to both companies…This acquisition provides a solution to recruiting patients faster, more efficiently and brings the most qualified patient in to trials, including hard to find patients.”
The acquisition includes MediciGroup affiliates MediciGlobal, and Access to Patients, and includes a lost-to-follow-up patient locate service that finds missing patients globally. Medici also manages over 30 global patient communities online and has implemented more than 200 programs for some of the world’s largest pharma companies since 1992.
BioClinica and Medici have already worked together on studies where the Medici Global team has leveraged data from BioClinica’s technology, and most recently their collaborations helped a company complete enrollment for a global study ahead of schedule.
Liz Moench, founder and CEO, Medici, added: “Together with BioClinica, our services will deliver an important model focused on speed, quality and cost efficiency for clinical trials implementation…When we integrate our recruitment metrics with BioClinica’s system, we can manage clinical trials in real time. This enables us to monitor enrollment rates by sites and drive performance at all levels – recruitment marketing and site performance from start to end.”
Moench will lead the BioClinica’s global patient recruitment and retention services at the company’s Pennsylvania-based headquarters.